as 11-08-2024 4:00pm EST
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
Founded: | 2009 | Country: | United States |
Employees: | N/A | City: | SEATTLE |
Market Cap: | 174.8M | IPO Year: | 2012 |
Target Price: | $6.25 | AVG Volume (30 days): | 462.9K |
Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.21 | EPS Growth: | N/A |
52 Week Low/High: | $0.62 - $2.31 | Next Earning Date: | 11-19-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
ATOS Breaking Stock News: Dive into ATOS Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
GlobeNewswire
5 days ago
GlobeNewswire
9 days ago
Zacks
12 days ago
GlobeNewswire
19 days ago
GlobeNewswire
25 days ago
GlobeNewswire
a month ago
Zacks
2 months ago
The information presented on this page, "ATOS Atossa Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.